GLS and Miyoshi myopathy: Some glutamine related targets are under investigation in this context, such as glutaminase inhibitor CB-839, which worked synergistically with several PIs at enhancing their cytotoxic activity against both sensitive and resistant MMCLs [35] and is currently in a phase 1 trial in combination with carfilzomib and dexamethasone for relapsed or refractory MM (NCT037986780).